2018 annual financial data
CRISPR Therapeutics 2018 Operating margin
CRISPR Therapeutics 2018 operating margin with verified reported values.
Direct answer
Operating margin was -5,087.8%.
Operating income was -158,943,000 USD and net income was -164,981,000 USD.
Operating cash flow was -96,239,000 USD.
Get free CRISPR Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 3,124,000 USD
- Operating income
- -158,943,000 USD
- Net income
- -164,981,000 USD
- Operating cash flow
- -96,239,000 USD